| Imagery Source: Wikimedia Commons / Eric Jones |
| Information Source: Abbot |
- Second-quarter reported sales growth of 7.4 per cent; organic sales growth of 6.9 per cent or 7.5 per cent excluding COVID-19 testing-related sales1
- Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26
- Reported gross margin of 52.7 per cent of sales; adjusted gross margin of 57.0 per cent, which reflects a 100 basis point increase
- Reported operating margin of 18.4 per cent of sales; adjusted operating margin of 22.9 per cent, which reflects a 100 basis point increase
|
| Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2025. |
- Second-quarter sales increased 7.4 per cent on a reported basis, 6.9 per cent on an organic basis, or 7.5 per cent when excluding COVID-19 testing-related sales1.
- Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year.
- First-half sales increased 5 per cent on a reported basis, 6.9 per cent on an organic basis, or 7.9 per cent when excluding COVID-19 testing-related sales2.
- Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
- Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint.
- In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex™ Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).
- In April, Abbott announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) clinical feasibility study. This study was the world's first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart's natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms.
- In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease.
- Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.
|
| "Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026." |
| SECOND-QUARTER BUSINESS OVERVIEW |
| Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis, excluding COVID-19 tests, is an appropriate way for investors to best understand the underlying performance of the company, as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to an endemic phase. |
| Note: To compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates, and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. |
| ABBOTT'S FINANCIAL GUIDANCE |
| Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales. |
| Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales. |
| Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32. |
| Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results by GAAP. |
| ABBOTT DECLARES 406th CONSECUTIVE QUARTERLY DIVIDEND |
| On June 13, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. |
| Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. |
| About Abbott: |
| Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. |
| Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. |
| For the full document, click the link below |
| Abbot |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
